← FDA DRUG APPROVALS

FDA ANDA · ANDA078378

REVONTO

dantrolene sodium

Sponsor: USWM

APPLICATION
ANDA078378
TYPE
ANDA
ORIGINAL APPROVAL
2007-07-24
LATEST ACTION
2024-11-22
ROUTE
INTRAVENOUS, INJECTION
DOSAGE FORM
INJECTABLE
MARKETING STATUS
Prescription

Products

REVONTOPrescription
DANTROLENE SODIUM 20MG/VIAL · INJECTABLE · INJECTION

Approval history

2024-11-22Labeling · Supplement 21 · standardAP
2015-05-27Labeling · Supplement 9 · standardAP
2010-02-16Labeling · Supplement 5AP
2010-02-16Labeling · Supplement 6AP
2010-02-16Labeling · Supplement 4AP
2007-07-24OriginalLetterAP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industryGMP disciplineFDA drug shortagesFDA enforcement & recalls

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →